In addition, by analyzing the expression correlation between immune cell signatures and FDX1 expression, we explored the relationship between FDX1 expression and the infiltration of immune cells in the tumor microenvironment and further clarified whether FDX1 could be used as a new type of glioma patient immunotherapy markers. The gene discussed is FDX1; the disease is central nervous system cancer.